Varenicline

• Smoking Cessation
• Nicotine Dependence
• Tobacco Use Disorder

Varenicline (Chantix) is an oral partial agonist at the alpha-4 beta-2 nicotinic acetylcholine receptor used as a pharmacotherapy aid for smoking cessation. It is the most effective single agent available for tobacco cessation in head-to-head trials and an essential tool for patients who have tried — and failed — to quit using behavioral counseling alone or nicotine replacement. Pairing varenicline with structured behavioral support roughly doubles long-term quit rates compared with either intervention alone, and the approach has revolutionized what was once considered a near-impossible behavior change for many heavy smokers.

Mechanism of Action

Varenicline binds with high affinity and selectivity to the alpha-4 beta-2 subtype of nicotinic acetylcholine receptors, the receptor most strongly implicated in nicotine reward. As a partial agonist, it produces a moderate, sustained dopaminergic response in the mesolimbic reward pathway — enough to blunt withdrawal symptoms and craving — while simultaneously occupying the receptor and blocking the much larger dopamine surge that nicotine from a cigarette would otherwise trigger. The result: smoking while on varenicline is less rewarding, and not smoking is more tolerable. Both effects are needed; either alone would be insufficient for the durable behavioral change required to quit.

This dual mechanism gives varenicline a higher quit rate than either nicotine replacement therapy or bupropion, the two main alternatives. Combination therapy — varenicline plus nicotine patch — has additional efficacy in some patients without prohibitive added side effects. Varenicline is renally cleared and does not significantly interact with the cytochrome P450 system, simplifying drug-interaction considerations compared with bupropion. The drug's pharmacokinetics are predictable, with an elimination half-life of about 24 hours that supports steady-state with once- or twice-daily dosing.

The receptor profile also explains why some patients describe a subjective change in how cigarettes "taste" or feel during varenicline therapy — the partial blockade dampens the conditioned reward signal that has been reinforced over decades of smoking. This subjective shift, combined with reduced craving intensity, makes the behavioral work of quitting more achievable.

Clinical Use

Varenicline is approved as an aid to smoking cessation in adults. Best results occur when paired with structured behavioral counseling — quitlines (1-800-QUIT-NOW), individual or group therapy, or digital cessation programs. The CDC tobacco cessation resources provide a comprehensive set of free patient tools, and the American Lung Association's Freedom From Smoking program is widely available.

Alternatives include bupropion sustained-release (which can be combined with nicotine replacement and has a useful role in patients with concurrent depression or weight-gain concerns) and the various forms of nicotine replacement therapy — patch, gum, lozenge, inhaler, nasal spray. Patch plus short-acting nicotine (gum or lozenge for breakthrough cravings) is a particularly effective NRT combination. For pregnant patients, behavioral therapy is first-line; nicotine replacement is generally preferred over varenicline if pharmacotherapy is needed because of more extensive pregnancy safety data. The article on vaping and e-cigarette health risks is relevant for patients considering switching nicotine sources rather than quitting outright — a popular but unproven cessation strategy that may delay full nicotine independence.

For patients with comorbid alcohol use disorder, naltrexone, acamprosate, or disulfiram can be combined with varenicline. Smoking cessation is also a critical component of cardiovascular and respiratory disease management — patients with coronary artery disease, chronic obstructive pulmonary disease, peripheral arterial disease, stroke, or atrial fibrillation gain enormous benefit from quitting at any age. For patients with diabetes, smoking cessation improves microvascular and macrovascular outcomes and complements the effects of agents like metformin and SGLT2 inhibitors. For patients on chronic anticoagulation with warfarin, apixaban, or rivaroxaban, quitting reduces both bleeding and thromboembolic risk.

How to Take It

Varenicline uses a one-week dose escalation to improve tolerability:

• Days 1–3: 0.5 mg once daily
• Days 4–7: 0.5 mg twice daily
• Day 8 onward: 1 mg twice daily

A quit date is set in one of two ways: start varenicline 1–2 weeks before the planned quit date (the traditional approach), or begin the drug and pick a quit day flexibly between days 8 and 35 (the more recent and equally effective gradual approach). Take with food and a full glass of water to reduce nausea, which is the most common side effect — affecting roughly 30% of patients but usually mild and transient. Evening doses should be taken in the early evening rather than at bedtime to minimize sleep disturbance and abnormal dreams, the second most common side effect.

Standard treatment duration is 12 weeks; an additional 12 weeks may be added in patients who successfully quit, to reduce relapse risk. Patients who slip during the first 12 weeks should not stop the drug — continued treatment with renewed quit attempts often succeeds. Patients should be told that mild withdrawal symptoms are still possible despite the drug, that cravings tend to come in waves lasting 3–5 minutes each, and that having a plan for high-risk situations (after meals, with coffee, with alcohol, with smoking friends) is critical. Distraction, deep breathing, and brief physical activity all help ride out cravings. Apps that track quit days and money saved can be powerful motivators; many patients do well with a daily journal entry recording cravings encountered and victories achieved.

Keep the medication in its original blister pack until use. Store at room temperature. If a dose is missed, take it as soon as remembered unless it is nearly time for the next dose; do not double up. The Starting Month Pak comes with the dose escalation built in, which simplifies the first weeks.

Monitoring and Follow-Up

No specific laboratory monitoring is required. The most important follow-up is clinical: check in at 1 week, 4 weeks, and 12 weeks (or sooner) to assess quit progress, side effects, and mood. Because nicotine is itself a CYP1A2 inducer, smoking cessation can raise levels of caffeine, theophylline, warfarin, and certain antipsychotics including clozapine and olanzapine — review concurrent medications when patients quit and watch for new symptoms suggesting elevated drug levels. Reduced caffeine intake by 30–50% is reasonable in the first weeks of cessation to avoid jitteriness misattributed to nicotine withdrawal. The understanding blood work article covers routine post-cessation labs, and home blood pressure monitoring is a good practice during this period.

Mood, sleep, and behavior should be assessed at each visit. The original boxed warning for serious neuropsychiatric events was removed in 2016 after the EAGLES trial showed no excess risk versus placebo, nicotine patch, or bupropion across patients with and without psychiatric history — but a small subset of patients still experience mood changes, vivid dreams, or agitation, so vigilance is appropriate. Patients with generalized anxiety disorder, major depressive disorder, or bipolar disorder can use varenicline but should have closer follow-up. Blood pressure should be checked because some patients experience modest elevations, and weight should be tracked because the typical 5–10 lb weight gain after smoking cessation is an issue many patients want addressed proactively. Our article on recognizing burnout and exhaustion is useful for patients quitting under stress, and our piece on chronic stress and physical illness provides context for how stress reduction supports cessation success.

Special Populations

For patients with creatinine clearance below 30 mL/min, start at 0.5 mg once daily and increase to a maximum of 0.5 mg twice daily. End-stage renal disease on hemodialysis: 0.5 mg once daily, given after the dialysis session. No hepatic adjustment is needed. Elderly patients require no specific adjustment but may be more sensitive to nausea, sleep effects, and dose-related neuropsychiatric symptoms.

Pregnancy data are limited; nicotine replacement therapy is generally preferred when pharmacotherapy is necessary, although the risks of continued smoking during pregnancy almost always outweigh the risks of any cessation pharmacotherapy. Lactation data are limited; weigh benefit and risk and consider that maternal smoking exposes the infant to nicotine and combustion products through both breast milk and secondhand smoke. Pediatric data did not support efficacy and the drug is not approved for patients under 18; adolescent cessation programs typically rely on behavioral counseling with nicotine replacement when pharmacotherapy is needed.

When to Contact Your Doctor

Call promptly for: thoughts of self-harm; marked depression; severe agitation or hostility; hallucinations; persistent vomiting or inability to keep food down; new seizure; or signs of allergic reaction such as facial swelling or skin peeling (Stevens-Johnson syndrome and other severe skin reactions are rare but reported). Report sleepwalking, severe nightmares disrupting sleep, chest pain, or new shortness of breath. Authoritative drug information is at MedlinePlus and the FDA prescribing label.

If you have questions about varenicline or your quit-smoking plan, our team at Zimmer Medical Group can help — contact us or schedule a visit.